Amgen Inc. $AMGN Stock: Mather Group LLC. Raises Stake

Mather Group LLC. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,591 shares of the medical research company’s stock after acquiring an additional 1,889 shares during the quarter. Mather Group LLC.’s holdings in Amgen were worth $4,464,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AMGN. West Wealth Group LLC lifted its holdings in shares of Amgen by 5.7% in the 3rd quarter. West Wealth Group LLC now owns 739 shares of the medical research company’s stock worth $312,000 after buying an additional 40 shares during the period. First Pacific Financial increased its stake in shares of Amgen by 25.0% during the third quarter. First Pacific Financial now owns 255 shares of the medical research company’s stock valued at $107,000 after buying an additional 51 shares during the period. Fortitude Family Office LLC increased its stake in shares of Amgen by 73.0% during the third quarter. Fortitude Family Office LLC now owns 2,028 shares of the medical research company’s stock valued at $855,000 after buying an additional 856 shares during the period. Johnson Bixby & Associates LLC increased its stake in shares of Amgen by 7.3% during the third quarter. Johnson Bixby & Associates LLC now owns 747 shares of the medical research company’s stock valued at $315,000 after buying an additional 51 shares during the period. Finally, Columbus Macro LLC raised its holdings in shares of Amgen by 1.1% in the third quarter. Columbus Macro LLC now owns 20,378 shares of the medical research company’s stock valued at $8,589,000 after acquiring an additional 225 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 1.9%

Shares of NASDAQ AMGN opened at $434.03 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market capitalization of $234.65 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The stock’s fifty day simple moving average is $415.11 and its two-hundred day simple moving average is $374.35. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen’s payout ratio is 62.65%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. Scotiabank upped their price objective on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Citigroup increased their target price on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. TD Cowen raised their target price on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Oppenheimer restated an “outperform” rating on shares of Amgen in a report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $387.93.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
• Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
• Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
• Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen

Insider Activity

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last quarter. 0.85% of the stock is owned by insiders.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.